Summary

Biosimilar drugs may offer affordable targeted therapies to patients across a spectrum of rheumatologic, oncologic, and gastrointestinal diseases, but they pose unique clinical trial design and licensing issues. Governments provide incentives for developing orphan drugs that would not otherwise be cost-effective to manufacture, allowing for the possibility of effective treatment options for rare diseases, including many rheumatologic conditions.